Pharma isn’t exactly known for its creativity, and brand-building ... In 2022, GSK rebranded in a bid to be seen as the “Tesla of pharma”. The company launched a new visual identity and ...

Oct 8 (Reuters) - GSK (GSK.L), opens new tab said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in its third season after patients ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of £15.50. The company’s shares closed today ...

In a report released today, Rajan Sharma from Goldman Sachs maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £18.00. The company’s shares opened ...

GlaxoSmithKline Pharma, celebrating 100 years in India, is shifting to a specialty-focused model by entering the oncology market and expanding its preventive healthcare through adult vaccines.

GSK has agreed to pay up to $2.2 billion to resolve ... Zantac has since returned to the market with a new formulation that does not include ranitidine. Companies facing federal litigation gained ...

The shots are important for both Pfizer and GSK as they look to build new franchises before top-selling drugs face generic competition later this decade. Pfizer is also contending with activist ...

A new $72 million award aims to double the U.S ... As part of the agreement, GSK, Sanofi, and CSL will produce extra bulk vaccine components tailored to the circulating strains of avian influenza.

GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals. The company's product portfolio includes prescription medicines and ...

Sept 18 (Reuters) - British drugmaker GSK (GSK.L), opens new tab said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued heartburn drug Zantac caused cancer.

GSK's specialty medicines segment showed strong performance, growing over 20% due to successful new launches. Additionally, GSK is currently undervalued, trading at £16.1, significantly below the ...

Miels said the new plan includes “changing our marketing mix to focus on segments who are tougher to activate.” Making Shields part of the marketing mix has enabled GSK to win mainstream media ...